These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26278120)

  • 1. Frequency of Administration of Erythropoiesis-Stimulating Agents for the Anaemia of End-Stage Kidney Disease in Dialysis.
    Nephrology (Carlton); 2015 Sep; 20(9):663-5. PubMed ID: 26278120
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients.
    Minutolo R; Borzumati M; Sposini S; Abaterusso C; Carraro G; Santoboni A; Mura C; Filiberti O; Santoro D; Musacchio R; Imperiali P; Fiorini F; De Nicola L; Russo D
    Am J Kidney Dis; 2016 Jul; 68(1):170-2. PubMed ID: 26879099
    [No Abstract]   [Full Text] [Related]  

  • 4. Understanding epoetin use: databases or clinical trials?
    Roger SD
    Nephrology (Carlton); 2007 Apr; 12(2):118-9. PubMed ID: 17371331
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
    Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
    J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
    Molina M; Navarro MJ; de Gracia C; Alvarez G; de Alarcon R; Garcia MA
    Ren Fail; 2008; 30(8):778-83. PubMed ID: 18791951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Adjuvant therapies to reduce erythropoiesis-stimulating agent dose requirements.
    Shah HH; Fishbane SN
    Semin Dial; 2013; 26(5):543-5. PubMed ID: 23763709
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoiesis stimulating agents and anaemia of end-stage renal disease.
    Schmid H; Schiffl H
    Cardiovasc Hematol Agents Med Chem; 2010 Jul; 8(3):164-72. PubMed ID: 20443766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Lupus Erythematosus as a Rare Cause of Anemia Resistant to Erythropoiesis-stimulating Agents.
    Yenigun EC; Bayrakci N; Cevher SK; Ozkayar N; Dede F
    Iran J Kidney Dis; 2016 Mar; 10(2):97-9. PubMed ID: 26921753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
    Wish JB
    Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
    Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
    Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain in recombinant human erythropoietin dosage with continuous intravenous intradialytic administration for the treatment of anaemia in end-stage renal disease.
    Liani M; Salvati F; Golato M; Cahen R
    Nephron; 1995; 69(2):189. PubMed ID: 7723913
    [No Abstract]   [Full Text] [Related]  

  • 14. Biosimilar epoetin zeta in nephrology - a single-dialysis center experience.
    Lonnemann G; Wrenger E
    Clin Nephrol; 2011 Jan; 75(1):59-62. PubMed ID: 21176751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure.
    Maxwell AP
    Kidney Int; 2002 Aug; 62(2):720-9. PubMed ID: 12110039
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
    Hörl WH; Vanrenterghem Y; Canaud B; Mann J; Teatini U; Wanner C; Wikström B
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure increase after erythropoietin injection in hemodialysis and predialysis patients.
    Noshad H
    Iran J Kidney Dis; 2013 May; 7(3):220-5. PubMed ID: 23689155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Woman with ESRD with Increasing Need for Erythropoietin to Maintain Hemoglobin.
    Koncicki HM; Fishbane S
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1173-1175. PubMed ID: 28522653
    [No Abstract]   [Full Text] [Related]  

  • 20. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
    Piotr B; Mariusz S; Jacek R
    Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.